Unknown

Dataset Information

0

A single nucleotide variant of human PARP1 determines response to PARP inhibitors.


ABSTRACT: The introduction of novel cancer drugs and innovative treatments brings great hope for cancer patients, but also an urgent need to match drugs to suitable patients, since certain drugs that benefit one patient may actually harm others. The newly developed poly-ADP ribose polymerase (PARP) inhibitors (PARPis) are a group of pharmacological enzyme inhibitors used clinically for multiple indications. Several forms of cancer tend to be PARP dependent, making PARP an attractive target for cancer therapy. Specifically, PARPis are commonly used in BRCA-associated breast cancers patients, since unrepaired single-strand breaks are converted into double-strand breaks and BRCA-associated tumors cannot repair them by homologous recombination so that PARPi leads to tumor cell death, by a mechanism called "Synthetic Lethality". Unfortunately, not all patients respond to PARPi, and it is not currently possible to predict who will or will not respond. Here, we present a specific genomic marker, which reflects a single-nucleotide polymorphism of human PARP1 and correlates in vitro with response to PARPi, throughout all indications. In addition, we report that this SNP is associated with re-shaping mRNA, and mRNA levels, and influences the final protein structure to expose new binding sites while hiding others. The status of the SNP is therefore critical to patients' care, as it relates responses to PARPi to the PARP1-SNP carried.

SUBMITTER: Cashman R 

PROVIDER: S-EPMC7184601 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

A single nucleotide variant of human PARP1 determines response to PARP inhibitors.

Cashman Rivki R   Zilberberg Alona A   Priel Avner A   Philip Hagit H   Varvak Alexander A   Jacob Avi A   Shoval Irit I   Efroni Sol S  

NPJ precision oncology 20200427


The introduction of novel cancer drugs and innovative treatments brings great hope for cancer patients, but also an urgent need to match drugs to suitable patients, since certain drugs that benefit one patient may actually harm others. The newly developed poly-ADP ribose polymerase (PARP) inhibitors (PARPis) are a group of pharmacological enzyme inhibitors used clinically for multiple indications. Several forms of cancer tend to be PARP dependent, making PARP an attractive target for cancer ther  ...[more]

Similar Datasets

| S-EPMC3528345 | biostudies-literature
2017-06-12 | GSE76981 | GEO
| S-EPMC8249464 | biostudies-literature
| S-EPMC9451145 | biostudies-literature
| S-EPMC4754671 | biostudies-literature
| S-EPMC9450093 | biostudies-literature
| S-EPMC7486119 | biostudies-literature
| S-EPMC4624427 | biostudies-literature
| S-EPMC7515702 | biostudies-literature
| S-EPMC5805596 | biostudies-literature